

SIRT2 promotes murine melanoma progression through natural killer cell inhibition

**Manchao Zhang<sup>1,3</sup>, Scarlett Acklin<sup>1,3</sup>, John Gillenwater<sup>1</sup>, Wuying Du<sup>1</sup>, Mousumi Patra<sup>1</sup>,  
Hao Yu<sup>1</sup>, Jianhua Yu<sup>2</sup>, and Fen Xia<sup>1\*</sup>.**

<sup>1</sup>Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA; <sup>2</sup>Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California


<sup>3</sup>These authors contributed equally.

**Correspondence:**

\*Fen Xia, MD, PhD, Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; Tel: 501-686-7100; Fax: 501-686-7285; E-mail:

FXia@uams.edu

## Supplemental Figure



### Supplemental Figure 1. Intracellular SIRT2 expression does not impact melanoma tumor progression

(A) Western blot showing decreased SIRT2 expression in *Sirt2*-KO B16-F10 cells following *Sirt2* knockout via CRISPR gene editing. *Sirt2*-OE B16-F10 cells overexpress SIRT2 as demonstrated by western blot following transfection with Flag-WT-*Sirt2*. (B) C57BL/6 WT mice were injected with WT, *Sirt2*-OE, and *Sirt2*-KO B16-F10 melanoma cells and tumor development and growth were monitored for 14 days. No significant difference in tumor progression was observed between the cell groups. Data points are mean values  $\pm$  SEM. n = 10. One-way ANOVA with post-hoc Tukey HSD test.